Cavion Raises $26.1M in Series A


What does Cavion do?

Cavion, is a clinical stage pharma company which is committed to providing patients with therapies for neurological disorders and cancer via drug development which selectively inhibit the T-type calcium channel. The company was built on the discovery by its founders that ion channels target solid tumor cancers. This is the 1st company at reinventing therapies engagging T-type calcium channel for solid tumors treatment. This innovative idea of pathologically proliferating, non-electrically excitable cells treatment by targeting ion channels has been a success already in pre-clinical trials and is being studied now for the Phase I safety and dose finding clinical trials in cancer of the brain. The company’s technology is intended for magnifying the combined radiation, chemotherapy and targeted therapies for all solid tumor cancers. They use clinical expertise and superior chemistry for delivering a novel class of drugs which will provide patients with neurological diseases treatments. While the T-type calcium channel is established in neurology, especially for neuropathic pain, this company is striving to bring the 1st non-opiod, non-addictive T-type calcium channel antagonist for patients suffering from neuropathic pain. T-type calcium channel, plays a role in many pathological conditions, this company is simultaneously developing therapies for additional neurological problems such as Parkinson’s diseases, essential tremor, Angelman syndrome and epilepsy.

How much Cavion was funded?

The company raised $26.1M in Series A on January 6, 2017 from Enso Ventures, Lilly Ventures and Novartis Venture Fund.

Previous funding

Undisclosed amount on December 22, 2005 from CIT GAP Funds

$5M on November 10, 2015

What is next for Cavion?

Cavion is developing new chemical entities which inhibit Cav3 channel for application in many therapeutic areas. As a part of the funding, Henry Skinner, Drs. Steven Hall and Sergei Petukhov  will join the company’s Board of Directors and Mr. David E. Gibson and CEO Andrew Krouse will  join as members of the Board.

More about Cavion

Cavion was founded in 2003 Timothy Macdonald, Andrew J. Krouse and  Lloyd Gray. It has its headquarters in Charlottesville, Virginia